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Abstract
Background. Extremely strong associations between male hormone-interfering drugs and meningiomas have 
been reported in two previous studies, but these findings are limited by small size of the study populations and 
possibly by surveillance- and selection bias. Thus, such possible and indeed very interesting association must be 
investigated in a large, unselected cohort. Accordingly, the aim of this study was to determine whether patients 
exposed to male hormone-interfering drugs had a higher risk of meningioma development in a nationwide cohort 
study.
Methods. A retrospective Danish nationwide cohort study with follow-up from January 1, 1996 to December 
31, 2016. Exposure was use of male hormone-interfering drugs (5-α-reductase-inhibitors, luteinizing hormone-
releasing hormone agonist, steroidal antiandrogen, and nonsteroidal antiandrogen). Hazard ratio of first-time 
diagnosis of meningioma according to drug use was estimated using Cox proportional hazards model with adjust-
ment for age and birth year.
Results. The cohort included 244,696 men of which 64,047 had used male hormone-interfering drugs. Overall 444 
meningiomas occurred during follow-up. No significant association was observed between use of male hormone-
interfering drugs and the occurrence of meningioma (hazard ratio 1.02, 95% confidence interval 0.82–1.27). Similar 
results were observed 0–1, 2–4, and 5+ years after first use. In explorative analyses, no elevated risk association 
was observed for specific drugs (5-α-reductase-inhibitors, luteinizing hormone-releasing hormone agonist, ste-
roidal antiandrogen, and nonsteroidal antiandrogen).
Conclusion. As opposed to previous studies, we found no evidence of an increased risk of meningioma in men 
treated with male hormone-interfering drugs.
Key Points
 • Male hormone-interfering drugs were not associated with an increased risk of 
meningioma.
 • No elevated risk of meningioma was observed for the specific subtypes of drugs.
 • Similar results were observed 0–1, 2–4, and 5+ years after first use.
Meningiomas (WHO grades I–III) are the most commonly 
diagnosed primary intracranial tumor1 with an incidence of 
2–7/100.000/year for women and 1–5/100.000/year for men.2 
They originate from arachnoid cap cells and may require 
surgical resection if the lesion is symptomatic and surgically 
accessible. Two previous studies, with different types of popu-
lations and design, have found highly increased risks of menin-
gioma development in patients treated with high-dose steroidal 
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antiandrogens (SAA), such as Cyproterone Acetate (relative 
risk [RR] 11.4 [95% CI: 4.3–30.8] and odds ratio [OR] 3.28 
[95% CI: 1.01–10.64], respectively).3,4 Some case-reports 
have described meningiomas among male-to-female trans-
sexual patients.5–7 Some of the meningiomas have been 
observed to either stop their growth or shrink in size after 
discontinuing of Cyproterone Acetate (SAA).5,7
One study did not find an association between the use 
of luteinizing hormone-releasing hormone (LHRH) or 
antiandrogens and the risk of meningiomas (OR 0.33 [95% 
CI: 0.07–1.66] and OR 3.82 [95% CI: 0.42–34.94], respec-
tively).8 Male hormone-interfering drugs are widely used 
in the treatment of prostate hyperplasia- and carcinoma, 
the latter being the second most frequent cancer among 
men in the world.9,10 Therefore, if the findings suggested by 
the aforementioned studies are true, it could have an im-
pact on a large number of men worldwide. However, these 
two studies are limited by small size of the study popula-
tions and possibly by surveillance- and selection bias. To 
overcome these limitations, this potential and indeed very 
interesting association must be investigated in a large, un-
selected cohort.
The unique Danish registers allows investigation of the 
potential association between male hormone-interfering 
drugs and the occurrence of meningiomas in a large unsel-
ected cohort with long-term follow-up and minimal selec-
tion- and surveillance bias.
Material and Methods
Data Sources
The following registers were used: The Civil Registration 
System (CRS) has existed since 1968 and is continuously 
updated regarding demographic information.11 Each in-
dividual in Denmark is given a social security number 
(CPR-number) that allows interlacement of the different re-
gisters. The National Patient Register (NPR) has registered 
all hospital admittances since 1977; furthermore, since 
1995 also emergency room visits and outpatient contacts, 
registered by the International Classification of Diseases 
(ICD-8 and ICD-10).12 The Danish Cancer Register (DCR) 
contains ICD-7 and ICD-10 as well as histologic diagnoses 
of all types of cancer as defined in the WHO classification 
systems. The National Prescription Register (NaPR) con-
tains information on all subscribed medicine in Denmark 
since 1995, according to the Anatomical Therapeutic 
Chemical Classification System (ATC codes),13 including in-
formation on date of dispensation, amount, and strength 
of the medicine.
Cohort
The main cohort consisted of all men living in Denmark, 
age 50 years or more, diagnosed with either prostatic hy-
perplasia (ICD-8: 60000, 60001, 60008, 60009, and ICD-10: 
DN40) or prostate carcinoma (ICD-8: 18599 and ICD-10: 
D61). Members of the cohort were identified by CPR-
number using CRS11 and NPR.12 Exclusion criteria were 
preexisting meningioma or neurofibromatosis type 2 diag-
nosis (ICD-10: DQ850) at start of follow-up, see Figure 1 in 
Supplementary Material.
Exposure: Male Hormone-Interfering Drugs
Use of male hormone-interfering drugs was determined 
using the NaPR.13 Male hormone-interfering drug use 
were identified by the ATC codes: G03HA (SAA), G04CB 
(5-α-reductase-inhibitors [5αRI]), L02AE (luteinizing hor-
mone releasing hormone agonist [LHRH-agonist]), and 
L02BB (nonsteroidal antiandrogen [NSAA]).
Outcome: Meningioma
By using DCR and NPR, all first-time meningioma were 
identified using ICD7: 193.2, 223, ICD-8: 19219, 22500, 
22501, 22502, 22503, 22507, 22509, 22520, 22521, 22522, 
22523, 22524, 22525, 22528, 22529, 22599, 23839 and ICD-
10: DD320, DD321, DD329, DC700, DC701, DC709.12 The 
ICD-8 and ICD-10 codes were automatically reported to The 
National Patient Register. The diagnosis of meningioma 
was based on diagnoses given by specialized medical doc-
tors of neurology, oncology, or neurosurgery. Surgical 
cases would also have a histological diagnosis (WHO 
Importance of the Study
Meningiomas have been suggested to occur in 
excess in patients treated with male hormone-
interfering drugs in two studies (relative risk 
[RR] 11.4 [95% CI: 4.3–30.8], and odds ratio 
[OR] 3.28 [95% CI: 1.01–10.64], respectively). 
These drugs are used in management of pros-
tate hyperplasia or—cancer, and if such asso-
ciation exist, it would affect millions of men 
worldwide. The aim of this study was to in-
vestigate the potential association between 
the use of male hormone-interfering drugs 
and meningiomas in an unselected large co-
hort without surveillance bias. This nation-
wide, register-based study included 244,696 
men with prostate hyperplasia or—cancer, of 
which 64,047 used male hormone-interfering 
drugs. As opposed to the previous studies, we 
found no evidence of an increased risk of me-
ningioma in men treated with male hormone-
interfering drugs, even 5+ years after first use. 
In explorative analyses, no elevated associated 
risk was observed for specific drugs.
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criteria) in the DCR. The same search was performed in 
the both registers to insure all cases of meningioma were 
identified.
Statistical Analyses
The individuals of the cohort were followed from January 
1, 1996, their 50th birthday or the day of inclusion of pros-
tate diagnosis, whichever was last, until one of the fol-
lowing events occurred: (a) diagnosis of a meningioma, (b) 
death, (c) emigration, (d) classified as missing person in 
CRS, (e) diagnosis of neurofibromatosis type II or (f) end of 
follow-up December 31, 2016. In all analyses, use of male 
hormone-interfering drug was treated as a time-dependent 
variable, such that cohort members are categorized as 
users after date of first redemption. For the main anal-
ysis a Cox-regression model with age as the underlying 
time scale and with the baseline hazard stratified by birth 
year was used to estimate the hazard ratio (HR) of menin-
gioma development according to use of male hormone-
interfering drug. The proportional hazards assumption of 
the main analysis was evaluated using a test for homoge-
neity of the HR in the age-intervals; 50–59, 60–69, 70–79, 
80–89, and more than 90 years of age. We analyzed if the 
HR of meningioma depended on time since first use of 
male hormone-interfering drug (in intervals 0–1, 2–4, and 5 
or more years of use, respectively). We estimated the HR of 
each of the male hormone-interfering drugs by limiting use 
to be defined by first the specific drug group and second 
the specific drug.
Furthermore, we restricted the cohort to include only 
those who had a prostate carcinoma or prostatic hyper-
plasia, respectively. Lastly, in a supplementary analysis 
among all men above 50 years of age we estimated age-
adjusted HRs of meningiomas of combined effects of pros-
tate diagnosis and male-hormone interfering drug use. In 
this analysis, both prostate diagnosis and MHID use were 
treated as time-varying exposures. All analyses were con-
ducted using SAS 9.4 (SAS Institute Inc., Cary, NC).
Ethics Statement
The study has been approved by the Danish Data Protection 
Agency, no. 2015-57-0102. Danish law does not require eth-
ical approval for register-based studies in Denmark.
Results
The cohort consisted of 244,696 patients. Of these 64,047 
had used male hormone-interfering drugs by the end of fol-
low-up (26.2%). The individual follow-up time varied from 
1 day to 7,670 days with a median of 2,122 days. The risk 
time for never users was 1.351 million years and 0.378 mil-
lion years for users. In the cohort, 444 patients were diag-
nosed with meningioma, consisting of 105 persons among 
users and 339 among never users. The mean age at which 
the patients were diagnosed with prostate disease was 69.9 
and for their meningioma diagnosis they were 75.6 years 
of age. Regarding drug use, Finasteride and Dutasteride, 
with 45,948 and 15,429 users, respectively, were the most 
prevalent drug types. The HRs of meningioma in patients 
diagnosed with prostatic hyperplasia and prostate car-
cinoma, according to ever use and time since first use of 
male hormone-interfering drugs are shown in Table 1. 
Users did not have an increased risk when compared to 
never users. No users with 0–1  years, 2–4  years or 5 or 
more years since first use, respectively, had an elevated 
rate of meningioma compared to never users (Table 1). 
HRs in the age intervals 50–59, 60–69, 70–79, 80–89, and 
more than 90 years of age were similar (P = .87, data not 
shown).
The HR of meningioma according to different types of 
male hormone-interfering drugs are presented in Table 2. 
There were no significant increased rates related to spe-
cific types of drugs.
In two analyses using only diagnosis of either prostate 
carcinoma or prostatic hyperplasia as inclusion criteria, 
users had a HR 1.03 (95 % CI: 0.65–1.62) and 1.10 (95 % CI: 
0.87–1.40), respectively compared to never users.
The analysis investigating combined effects of prostate 
diagnosis and MHID use is shown in Table 3. Here, it is 
shown that among men not treated with male-hormone in-
terfering drugs the risk of meningioma was higher 1.78 (95 
% CI: 1.57–2.01) if they had a prostate diagnosis.
Discussion
In this large unselected nationwide cohort study of pros-
tate patients, we investigated the risk of meningioma as-
sociated with overall use of male hormone-interfering 
  
Table 1. Hazard ratio (HR) of meningioma in patients diagnosed with prostatic hyperplasia and prostate carcinoma, according to the use-, and time 
since first use of male hormone-interfering drugs compared to never users
Time since first use Risk time (person-years) Meningioma cases HR 95 % CI
Never use 1,351,000 339 1 Reference
Ever use 378,000 105 1.02 (0.82–1.27)
0–1 years 76,000 19 0.97 (0.61–1.55)
2–4 years 103,000 27 1.01 (0.68–1.50)
5+ years 199,000 59 1.04 (0.79–1.39)
CI, confidence interval; HR, hazard ratio.
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drugs as well as the risks associated with use of the indi-
vidual subtypes: SAA, 5αRI, LHRH-agonist, and NSAA. No 
evidence was found of an increased short- or long-term 
risk of meningioma in men treated with male hormone-
interfering drugs, overall (HR: 1.02, 95 % CI: 0.82–1.27) or 
within subtypes. This is to our knowledge the first large 
scale population-based cohort study investigating this im-
portant research question of relevance for all users of male 
hormone-interfering drugs.
Only the three aforementioned studies have previ-
ously investigated the association between use of male 
hormone-interfering drugs and risk of meningiomas.3,4 
The first was a Spanish retrospective cohort study, per-
formed in a Spanish primary care database (BIFAP),3 which 
showed a highly increased rate ratio (RR: 11.4, 95% CI: 4.3–
30.8) of meningioma among 2,474 users of high-dose SAA 
as compared to never users.
The other study, a retrospective cohort study with a 
nested case–control analysis, was conducted using indi-
viduals identified from The Health Improvement Network 
(THIN) UK primary care database.4 This study involved 196 
meningioma patients and 2,653 controls. The result of this 
study showed an OR of 3.28 (95% CI: 1.01–10.64) for users 
of SAAs compared to never users.4
The two studies were both limited to only four exposed 
cases of meningiomas and the higher risk among users 
reported in these studies may be because users were 
compared to the general population.4 Thus, there might 
have been an increased tendency to refer the patients in 
the exposed group in the second study to brain imaging 
studies, because of their active cancer diagnosis, resulting 
in surveillance bias.
The analysis investigating combined effects of prostate 
diagnosis and MHID use shows that men with prostate 
  
Table 2. Hazard ratio (HR) of meningioma in patients with prostatic hyperplasia and prostate carcinoma, according to ever use of different types of 
male hormone-interfering drugs, compared to never users
Types of male-hormone  
interfering drugs
Risk time (person-years)* Number of meningiomas* HR† (95% CI‡)
5-α-Reductase-inhibitors 359,428 99 1.01 (0.80–1.26)
 Finasteride 299,454 77 0.94 (0.74–1.21)
 Dutasteride 78,576 30 1.30 (0.89–1.91)
LHRH-agonist 5,109 ˂5§ 1.63 (0.40–6.53)
 Buserelin 254 0 —  
 Leuprorelin 741 0 —  
 Goserelin 3,953 ˂5§ 2.05 (0.51–8.21)
 Triptorelin 256 0 —  
Steroidal antiandrogens
 Cyproterone 6,141 ˂5§ 1.81 (0.58–5.64)
Nonsteroidal antiandrogen 15,751 6 1.43 (0.64–3.21)
 Flutamide 6,548 0 —  
 Bicalutamide 9,887 6 2.16 (0.97–4.85)
 Enzalutamide 1 0 —  
 Nilutamide 9 0 —  
*Some patients were exposed to more than one type of drug, therefore the total numbers do not add.
†HR, hazard ratio.
‡CI, confidence interval.
§Due to Danish law it is not permitted to specify counts less than 5.
  
  
Table 3. Age-adjusted hazard ratios (HRs) of meningiomas of combined effects of prostate diagnosis and male-hormone interfering drug use
HR* (95% CI†)
Background population controls not treated with MHID‡ 1.00 (Ref)  
Hospital diagnosis of prostate disease not treated with MHID 1.78 (1.57–2.01)
Hospital diagnosis of prostate disease treated with MHID 1.75 (1.43–2.15)
*HR, hazard ratio.
†CI, confidence interval.
‡Male-hormone interfering drugs.
  
D
ow
nloaded from
 https://academ
ic.oup.com
/noa/article-abstract/1/1/vdz046/5625834 by guest on 18 M
ay 2020
5Giraldi et al. Male hormones and meningiomas
N
eu
ro-O
n
colog
y 
A
d
van
ces
diagnosis have higher incidence of meningioma than men 
without diagnosis. This most likely reflect the well-known 
surveillance bias that arises due to a higher level of aware-
ness of symptoms in patients with regular contacts to the 
health care system. A  causal relation between prostate 
disease and meningiomas is less likely as systemic base-
line hormone levels to our knowledge are not different 
between men with prostate cancer and controls. This is 
supported by the review by Burton et al.14: “a pooled anal-
ysis of 18 pooled prospective observational studies has 
not shown circulating androgen levels to be associated 
with risk of prostate cancer.” It is also points to the fact that 
the development of prostate cancer is more influenced by 
the level of intraprostatic conversion of testosterone to 
5α-dihydrotestosterone, than by the circulating androgen 
levels. In either case an analysis estimating the effect of 
MHID use on meningioma risk may well be confounded 
if not taking prostate diagnosis into account. Therefore, 
in our main analyses we restricted the study to men with 
prostatic disease to overcome this surveillance bias, and 
found no significant association between treatment and 
meningiomas. However, our study included only few cases 
exposed to SAA.
The third was an American retrospective interview, 
identifying patients through the Rapid Case Ascertainment 
system and state cancer register.8 This study involved 456 
meningioma patients and 452 controls who were iden-
tified by a consulting firm by random-digit dialing. This 
study investigated the use of LHRH and antiandrogen and 
risk of meningioma. There were no significant associations 
detected for either LHRH (OR 0.33 [95% CI: 0.07–1.66]) or 
antiandrogen (OR 3.82 [95% CI: 0.42–34.94]). The study was 
limited by low prevalence of exposed patients (exposed 
patients were 2 and 4, respectively), thus, the power to de-
tect an association was not adequate. Furthermore, it was 
not specified if the antiandrogens were either steroidal, 
nonsteroidal, or both combined.
The study from the UK also examined the risk of me-
ningioma among users of LHRH-agonists and NSAAs and 
found no significantly increased risks.4 Our study sup-
ported this finding. To the best our knowledge, our study is 
the first to investigate the association between 5αRIs and 
meningiomas.
A potential limitation of our study is that patients may 
die with an undiagnosed meningioma, but the mean age 
for our cohort is relatively high when included in the study 
(69.9  years old). Furthermore, prostate carcinoma has a 
long overall survival with 10‐ and 15‐year relative survival 
rates being 97.8% and 91.4%, respectively.15 This means 
that most of the patients in our cohort would survive long 
enough to be diagnosed with a potential meningioma, 
thereby reducing this potential limitation. Our study was 
limited by the small number of users of some drug types to 
determine specific risks of these types.
Several strengths substantiate this study. The access to 
detailed and complete register information of medicine-
use allowed construction of a complete cohort of male 
hormone-interfering drug users within the same disease 
groups, thereby diminishing the important limitations of 
surveillance bias, as seen in the previous studies. This is 
very important, since a large number of incidental menin-
gioma patients are diagnosed during diagnostic work-up 
related to cancers (diagnostic workup for brain metas-
tases). The fact that there, in Denmark, is free universal 
access to healthcare ensured that patients displaying new 
neurological symptoms undergoes relevant diagnostic 
tests. Furthermore, patients diagnosed with neurofibroma-
tosis type II or meningioma at baseline were excluded.
In conclusion, we found no evidence of increased short- 
or long-term risk of meningioma in prostate patients 
treated with male hormone-interfering drugs.
Supplementary Material
Supplementary material is available online at Neuro-
Oncology (http://neuro-oncology.oxfordjournals.org/).
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